11th May 2017 12:21
Realm Therapeutics plc
("Realm Therapeutics" or the "Company")
Notice of Annual General Meeting
11 May 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announces that the 2017 Annual General Meeting will be held at 10.00 am on Tuesday, 6 June 2017, at the offices of CMS Cameron McKenna Nabarro Olswang LLP, Cannon Place, 78 Cannon Street, EC4N 6AF London. The 2017 Notice of Annual General Meeting and Form of Proxy will be available today on the Company's website at www.realmtx.com and are being posted to shareholders today.
Enquiries:
Realm Therapeutics plc | +44 (0) 20 3727 1000 | |
Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer | ||
FTI Consulting | +44 (0) 20 3727 1000 | |
Simon Conway / Mo Noonan | ||
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 | |
Aubrey Powell / Lauren Kettle | ||
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.
Related Shares:
RLM.L